07:57 AM EST, 11/12/2024 (MT Newswires) -- Vesalius Therapeutics said Tuesday it has formed a strategic alliance with GSK (GSK) to develop novel treatments for Parkinson's disease and another "undisclosed" neurodegenerative indication.

"Vesalius will leverage its platform to identify novel intervention points in Parkinson's disease and one additional indication in neurodegeneration, and GSK will have the option to advance programs against those novel intervention points," Vesalius said in a news release.

"Our alliance with Vesalius underscores GSK's commitment to the discovery and development of disease modifying therapeutics in areas of significant unmet need," said Kaivan Khavandi, global head of respiratory/immunology research and development at GSK.

Price: 35.48, Change: -0.87, Percent Change: -2.39